Skip to content

Upadacitinib in adult patients with erosive mucosal Lichen Planus and Lichen Planopilaris: a prospective multicenter randomized placebo-controlled study. (Upa30-LP)

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522870-35-00
Enrollment
56
Registered
2026-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lichen

Brief summary

Achievement of IGA response (absolute IGA score ≤2) at Week 16

Detailed description

Achievement of 2 points improvement in the IGA at Week 32, Achievement of DLQI 0/1 score at Week 16 and Week 32, PGIS at Week 16 and Week 32, PGIC at Week 16 and Week 32, Adverse events, laboratory values, vital signs from baseline to end of study visit analysis, Absolute and relative change in REU, OLPSSM and NRS score at Week 16 and Week 32, Absolute and relative change in LPPAI and SCALPDEX Questionnaire score at Week 16 and Week 32

Interventions

DRUGPlacebo is identifical in composition to rinovq but does not contain the substance medical

Sponsors

Centre Hospitalier Universitaire De Nice
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Achievement of IGA response (absolute IGA score ≤2) at Week 16

Secondary

MeasureTime frame
Achievement of 2 points improvement in the IGA at Week 32, Achievement of DLQI 0/1 score at Week 16 and Week 32, PGIS at Week 16 and Week 32, PGIC at Week 16 and Week 32, Adverse events, laboratory values, vital signs from baseline to end of study visit analysis, Absolute and relative change in REU, OLPSSM and NRS score at Week 16 and Week 32, Absolute and relative change in LPPAI and SCALPDEX Questionnaire score at Week 16 and Week 32

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 10, 2026